| 9001 | CD27/TNFRSF13B ratio | GCST90313777 | 2.52e-03 |
| 9002 | DTI autoptx L2 ptr r tract | GCST90385186 | 2.52e-03 |
| 9003 | 1,5-anhydroglucitol (1,5-ag) levels | GCST90243529 | 2.51e-03 |
| 9004 | Secondary diabetes mellitus (PheCode 249) | GCST90475655 | 2.51e-03 |
| 9005 | Neurociticism | GCST006940 | 2.51e-03 |
| 9006 | Glycoprotein acetyls levels | GCST90497320 | 2.50e-03 |
| 9007 | Qualifications - None of the above | Education | UKBB00000729 | 2.50e-03 |
| 9008 | FAS levels | GCST90469192 | 2.50e-03 |
| 9009 | RP2 levels | GCST90470493 | 2.50e-03 |
| 9010 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T88 | ECGU000088 | 2.50e-03 |
| 9011 | Clinical LDL cholesterol levels | GCST90497223 | 2.50e-03 |
| 9012 | Free cholesterol in large VLDL (UKB data field 23500) | GCST90269597 | 2.49e-03 |
| 9013 | DNA methylation GrimAge acceleration | GCST90014288 | 2.49e-03 |
| 9014 | Phospholipid levels in very large HDL | GCST90093012 | 2.49e-03 |
| 9015 | PPP1R2/TBL1X ratio | GCST90315720 | 2.49e-03 |
| 9016 | Concentration of LDL particles | GCST90498418 | 2.48e-03 |
| 9017 | Blood cell traits latent factor 7 (white cell) | GCST90559249 | 2.48e-03 |
| 9018 | LDL cholesterol levels | GCST90498353 | 2.47e-03 |
| 9019 | NECTIN2/SPON2 ratio | GCST90315530 | 2.47e-03 |
| 9020 | DTI TBSS L2 Superior cerebellar peduncle R | GCST90384488 | 2.46e-03 |
| 9021 | GSN levels | GCST90469409 | 2.46e-03 |
| 9022 | EDA2R levels | GCST90469067 | 2.46e-03 |
| 9023 | Cholesterol to total lipids ratio in medium HDL | GCST90092893 | 2.45e-03 |
| 9024 | DYNLT1 levels | GCST90469057 | 2.45e-03 |
| 9025 | CANT1/HSPB1 ratio | GCST90313617 | 2.45e-03 |
| 9026 | ACVRL1 levels | GCST90468211 | 2.44e-03 |
| 9027 | Phospholipids in very large HDL | GCST90500458 | 2.44e-03 |
| 9028 | CD84/CDKN1A ratio | GCST90313909 | 2.44e-03 |
| 9029 | Concentration of HDL particles | GCST90092826 | 2.43e-03 |
| 9030 | Phospholipids to Total Lipids in Large LDL percentage | GCST90498058 | 2.43e-03 |
| 9031 | 5alpha-androstan-3beta,17beta-diol monosulfate (2) levels | GCST90199855 | 2.43e-03 |
| 9032 | DTI TBSS FA Posterior thalamic radiation L | GCST90384409 | 2.43e-03 |
| 9033 | ACY1/GSTA1 ratio | GCST90313163 | 2.43e-03 |
| 9034 | PLA2G4A levels | GCST90470248 | 2.43e-03 |
| 9035 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T85 | ECGU000085 | 2.42e-03 |
| 9036 | Glycoprotein acetyls levels | GCST90092821 | 2.42e-03 |
| 9037 | MARCO/SIGLEC1 ratio | GCST90315387 | 2.42e-03 |
| 9038 | Total Lipids in LDL | GCST90498405 | 2.42e-03 |
| 9039 | Lymphangioleiomyomatosis (sporadic) | GCST008311 | 2.42e-03 |
| 9040 | CLIC5 levels | GCST90421740 | 2.42e-03 |
| 9041 | Concentration of large VLDL particles | GCST90498226 | 2.41e-03 |
| 9042 | MED18/SMAD1 ratio | GCST90315413 | 2.41e-03 |
| 9043 | CSF1/LTBR ratio | GCST90314287 | 2.41e-03 |
| 9044 | Volume of left central nucleus | GCST90474883 | 2.41e-03 |
| 9045 | Diacylglycerol_44:6_[M+H-H2O]1+ levels | GCST90060245 | 2.41e-03 |
| 9046 | Sphingomyelin_38:1_[M+H]1+ levels | GCST90060306 | 2.41e-03 |
| 9047 | Cholesteryl Esters in Medium HDL | GCST90498532 | 2.41e-03 |
| 9048 | Abdominal and pelvic pain | Symptoms and signs involving the digestive system and abdomen | UKBB00000001 | 2.41e-03 |
| 9049 | Malignant neoplasm of oropharynx, excluding all cancers (controls excluding all cancers) | FING00000768 | 2.40e-03 |
| 9050 | CD69/NFATC1 ratio | GCST90313879 | 2.40e-03 |
| 9051 | ATP5IF1/METAP1D ratio | GCST90313391 | 2.40e-03 |
| 9052 | ICA1/TANK ratio | GCST90315112 | 2.40e-03 |
| 9053 | Free cholesterol in medium HDL | GCST90498562 | 2.40e-03 |
| 9054 | F9/PROC ratio | GCST90314748 | 2.39e-03 |
| 9055 | T1 CAT volume L IX | GCST90384133 | 2.39e-03 |
| 9056 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502389 | 2.38e-03 |
| 9057 | CDH1 levels | GCST90468670 | 2.38e-03 |
| 9058 | FYB1 levels | GCST90469284 | 2.38e-03 |
| 9059 | BAG6/USP8 ratio | GCST90313451 | 2.38e-03 |
| 9060 | Sphingomyelin_32:1_[M+H]1+ levels | GCST90060225 | 2.37e-03 |
| 9061 | Bread intake | Diet | UKBB00000105 | 2.37e-03 |
| 9062 | SFTPA2 levels | GCST90470613 | 2.37e-03 |
| 9063 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475452 | 2.37e-03 |
| 9064 | Triglycerides to total lipids in large VLDL percentage (UKB data field 23593) | GCST90269690 | 2.37e-03 |
| 9065 | APOA levels | GCST90468061 | 2.37e-03 |
| 9066 | CCS levels | GCST90468594 | 2.37e-03 |
| 9067 | Certain disorders involving the immune mechanism | FING00000264 | 2.37e-03 |
| 9068 | Other non-epithelial cancer of skin | neoplasms | UKBB00000615 | 2.37e-03 |
| 9069 | Essential tremor (PheCode 333.1) | GCST90475832 | 2.36e-03 |
| 9070 | Reticulocyte count | GCST90002405 | 2.36e-03 |
| 9071 | Acute upper respiratory infections of multiple and unspecified sites | FING00000035 | 2.35e-03 |
| 9072 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668524 | 2.34e-03 |
| 9073 | ABHD14B/CCS ratio | GCST90313139 | 2.34e-03 |
| 9074 | PLA2G7 levels | GCST90470249 | 2.33e-03 |
| 9075 | LY6G6C levels | GCST90241830 | 2.33e-03 |
| 9076 | High light scatter reticulocyte percentage (UKB data field 30290) | GCST90468077 | 2.32e-03 |
| 9077 | GUCA2A/LGALS4 ratio | GCST90314998 | 2.32e-03 |
| 9078 | DTI TBSS L3 Posterior corona radiata L | GCST90384551 | 2.32e-03 |
| 9079 | AIFM1 levels | GCST90468268 | 2.31e-03 |
| 9080 | Body mass index | GCST90502912 | 2.31e-03 |
| 9081 | All dysplastic lesions of the cervix uteri | FING00000060 | 2.31e-03 |
| 9082 | Phospholipids in very small VLDL (UKB data field 23518) | GCST90269615 | 2.31e-03 |
| 9083 | DAPK2 levels | GCST90240877 | 2.31e-03 |
| 9084 | Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skin | UKBB00000613 | 2.30e-03 |
| 9085 | GP2/LGALS4 ratio | GCST90314960 | 2.30e-03 |
| 9086 | Phosphatidylcholine (18:0_20:3) levels | GCST90024876 | 2.30e-03 |
| 9087 | PCDH17/SEMA7A ratio | GCST90315605 | 2.30e-03 |
| 9088 | Maximum digits remembered correctly | Numeric memory | UKBB00000430 | 2.27e-03 |
| 9089 | FHIT levels | GCST90469238 | 2.26e-03 |
| 9090 | Vitamin B12 deficiency anaemia | FING00001441 | 2.26e-03 |
| 9091 | Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486) | GCST90269583 | 2.25e-03 |
| 9092 | Sporadic miscarriage | GCST011888 | 2.25e-03 |
| 9093 | Gastric ulcer | GCST90270927 | 2.24e-03 |
| 9094 | ALDH1A1/CA2 ratio | GCST90313243 | 2.24e-03 |
| 9095 | Total bile acid levels in pregnancy | GCST90454198 | 2.23e-03 |
| 9096 | F-seafood liking (derived food-liking factor) | GCST90094836 | 2.23e-03 |
| 9097 | C5 levels | GCST90468500 | 2.23e-03 |
| 9098 | PROK1 levels | GCST90470336 | 2.22e-03 |
| 9099 | Non-allergic asthma (mode) (more control exclusions) | FING00000869 | 2.22e-03 |
| 9100 | Neuroticism score | Mental health | UKBB00000496 | 2.22e-03 |
| 9101 | Major depressive disorder | GCST009979 | 2.22e-03 |
| 9102 | TGFA levels | GCST90470842 | 2.21e-03 |
| 9103 | Sardines liking | GCST90094830 | 2.21e-03 |
| 9104 | Cancer of bladder (PheCode 189.2) | GCST90475598 | 2.20e-03 |
| 9105 | APCS levels | GCST90428463 | 2.20e-03 |
| 9106 | RAB31 levels | GCST90087552 | 2.20e-03 |
| 9107 | Occupation and workplace environment (confirmatory factor analysis Factor 5) | GCST90309340 | 2.20e-03 |
| 9108 | Tea intake | Diet | UKBB00000814 | 2.19e-03 |
| 9109 | platelet count (mean, inv-norm transformed) | GCST90476299 | 2.19e-03 |
| 9110 | Metabolic syndrome | GCST009602 | 2.19e-03 |
| 9111 | CCN2/SPINT2 ratio | GCST90313716 | 2.19e-03 |
| 9112 | ARHGAP25/RNF41 ratio | GCST90313345 | 2.18e-03 |
| 9113 | ADAM23 levels | GCST90240922 | 2.18e-03 |
| 9114 | total cholesterol (maximum, inv-norm transformed) | GCST90476420 | 2.18e-03 |
| 9115 | COL1A1 levels | GCST90240744 | 2.18e-03 |
| 9116 | Triglycerides in small HDL | GCST90499519 | 2.17e-03 |
| 9117 | BCR/DECR1 ratio | GCST90313489 | 2.17e-03 |
| 9118 | Ground coffee consumption | GCST90132976 | 2.16e-03 |
| 9119 | IL27 levels | GCST90012017 | 2.16e-03 |
| 9120 | BTN2A1/CSF1 ratio | GCST90313541 | 2.16e-03 |
| 9121 | FOXO1/NFATC1 ratio | GCST90314873 | 2.16e-03 |
| 9122 | Diabetes | GCST90468124 | 2.15e-03 |
| 9123 | Hepatomegaly (PheCode 573.3) | GCST90476092 | 2.15e-03 |
| 9124 | Benign neoplasm of eye (PheCode 224) | GCST90475626 | 2.15e-03 |
| 9125 | Celiac disease (PheCode 557.1) | GCST90044158 | 2.15e-03 |
| 9126 | Triglycerides in medium HDL | GCST90498667 | 2.15e-03 |
| 9127 | All dysplastic lesions of the cervix uteri, vagina or vulva | FING00000061 | 2.15e-03 |
| 9128 | MESD/WWP2 ratio | GCST90315426 | 2.15e-03 |
| 9129 | RBFOX3 levels | GCST90470432 | 2.14e-03 |
| 9130 | potassium (mean, inv-norm transformed) | GCST90476307 | 2.14e-03 |
| 9131 | PM20D1 levels | GCST90470268 | 2.14e-03 |
| 9132 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T87 | ECGU000087 | 2.13e-03 |
| 9133 | Vertiginous syndromes and other disorders of vestibular system (PheCode 386) | GCST90475905 | 2.13e-03 |
| 9134 | SCGB1A1 levels | GCST90470540 | 2.13e-03 |
| 9135 | GM3 ganglioside (d18:1/24:0) levels | GCST90024729 | 2.12e-03 |
| 9136 | SLITRK1 levels | GCST90470669 | 2.11e-03 |
| 9137 | Non-mucinous epithelial ovarian cancer | GCST90244167 | 2.11e-03 |
| 9138 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502372 | 2.11e-03 |
| 9139 | PDCD1/TNFRSF8 ratio | GCST90315610 | 2.11e-03 |
| 9140 | Dermatitis due to ingested food | FING00000403 | 2.10e-03 |
| 9141 | All pneumoniae | FING00000065 | 2.10e-03 |
| 9142 | Emotionally unstable personality disorder | FING00000495 | 2.09e-03 |
| 9143 | Alanine aminotransferase levels | GCST90018723 | 2.09e-03 |
| 9144 | CD58/IL10RB ratio | GCST90313850 | 2.09e-03 |
| 9145 | Cholesteryl Esters in Medium HDL | GCST90498538 | 2.09e-03 |
| 9146 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T488 | ECGU000488 | 2.09e-03 |
| 9147 | IDP dMRI TBSS OD Superior fronto-occipital fasciculus R | GCST90004444 | 2.09e-03 |
| 9148 | Hereditary hemolytic anemias (PheCode 282) | GCST90475779 | 2.09e-03 |
| 9149 | B4GALT1/IFNGR1 ratio | GCST90313430 | 2.08e-03 |
| 9150 | IDP dMRI TBSS MO Posterior limb of internal capsule L | GCST90003971 | 2.08e-03 |
| 9151 | FURIN/PLA2G15 ratio | GCST90314887 | 2.08e-03 |
| 9152 | Non-cancer illness code, self-reported - type 2 diabetes | Medical conditions | UKBB00000522 | 2.07e-03 |
| 9153 | Statin-associated type 2 diabetes mellitus | GCST90652517 | 2.07e-03 |
| 9154 | MMP1/SERPINB6 ratio | GCST90315462 | 2.07e-03 |
| 9155 | Cancer of prostate (PheCode 185) | GCST90041853 | 2.06e-03 |
| 9156 | EFNA4/TNFRSF10B ratio | GCST90314605 | 2.06e-03 |
| 9157 | ENO2/FXYD5 ratio | GCST90314659 | 2.05e-03 |
| 9158 | Diacylglycerol_42:7_[M+H-H2O]1+ levels | GCST90060226 | 2.05e-03 |
| 9159 | Special factor anxiety/tension in mitochondrial haplogroup U | GCST90264127 | 2.05e-03 |
| 9160 | PCDH17/PTPRM ratio | GCST90315603 | 2.04e-03 |
| 9161 | CD69/PLXNB3 ratio | GCST90313881 | 2.04e-03 |
| 9162 | MSRA/SNAP29 ratio | GCST90315500 | 2.03e-03 |
| 9163 | CFD levels | GCST90468725 | 2.03e-03 |
| 9164 | MFGE8 levels | GCST90469900 | 2.03e-03 |
| 9165 | PRSS2 levels | GCST90243126 | 2.03e-03 |
| 9166 | Omega-3 fatty acids to total fatty acids percentage | GCST90499163 | 2.02e-03 |
| 9167 | DTI autoptx MD str l tract | GCST90385243 | 2.02e-03 |
| 9168 | Chronotype | GCST003837 | 2.02e-03 |
| 9169 | Abnormal movement (PheCode 350) | GCST90475840 | 2.02e-03 |
| 9170 | Benign neoplasm of eye, uveal (PheCode 224.1) | GCST90475629 | 2.01e-03 |
| 9171 | ZP3 levels | GCST90471105 | 2.01e-03 |
| 9172 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T482 | ECGU000482 | 2.01e-03 |
| 9173 | T1 FreeSurfer a2009s rh Pole occipital area | GCST90384931 | 2.01e-03 |
| 9174 | SERPINA5 levels | GCST90470585 | 2.01e-03 |
| 9175 | GZMB/IL15 ratio | GCST90315015 | 2.00e-03 |
| 9176 | Free Cholesterol in LDL | GCST90498388 | 2.00e-03 |
| 9177 | aparc-DKTatlas rh area postcentral | GCST90003285 | 2.00e-03 |
| 9178 | MED18/TBL1X ratio | GCST90315415 | 1.99e-03 |
| 9179 | Dementia due to Parkinson's disease (more control exclusions) | FING00000392 | 1.99e-03 |
| 9180 | B3GNT7 levels | GCST90468411 | 1.98e-03 |
| 9181 | Roast chicken liking | GCST90094821 | 1.97e-03 |
| 9182 | Other/unspecified rheumatoid arthritis | FING00001126 | 1.97e-03 |
| 9183 | Feeling tense | GCST006952 | 1.96e-03 |
| 9184 | SEMA4D levels | GCST90470573 | 1.95e-03 |
| 9185 | Pain in limb (PheCode 773) | GCST90476270 | 1.95e-03 |
| 9186 | IMMT levels | GCST90469609 | 1.94e-03 |
| 9187 | ICA1/MVK ratio | GCST90315108 | 1.94e-03 |
| 9188 | Colitis, primary sclerosing, strict definition | FING00000313 | 1.94e-03 |
| 9189 | Total lipids in large VLDL (UKB data field 23496) | GCST90269593 | 1.93e-03 |
| 9190 | UCMA levels | GCST90243285 | 1.93e-03 |
| 9191 | Cholesterol in small VLDL (UKB data field 23512) | GCST90269609 | 1.93e-03 |
| 9192 | GSTA1/SULT2A1 ratio | GCST90314996 | 1.93e-03 |
| 9193 | DTI TBSS MD Anterior corona radiata L | GCST90384595 | 1.93e-03 |
| 9194 | CRELD2/F2R ratio | GCST90314254 | 1.93e-03 |
| 9195 | Linoleic acid to total fatty acids percentage | GCST90502023 | 1.92e-03 |
| 9196 | CCL28/PDGFB ratio | GCST90313695 | 1.91e-03 |
| 9197 | ESAM/FUT8 ratio | GCST90314711 | 1.91e-03 |
| 9198 | Ever unenthusiastic/disinterested for a whole week | Mental health | UKBB00000226 | 1.91e-03 |
| 9199 | TFF1 levels | GCST90470835 | 1.90e-03 |
| 9200 | STX8 levels | GCST90470776 | 1.90e-03 |
| 9201 | Moderate-to-vigorous intensity physical activity during leisure time | GCST90104341 | 1.90e-03 |
| 9202 | CD69/TIA1 ratio | GCST90313888 | 1.89e-03 |
| 9203 | X-21285 levels | GCST90200576 | 1.89e-03 |
| 9204 | Chronic bronchitis (PheCode 496.2) | GCST90476029 | 1.89e-03 |
| 9205 | total cholesterol (minimum, inv-norm transformed) | GCST90476427 | 1.88e-03 |
| 9206 | Dihexosylceramide (d18:1/24:0) levels | GCST90025349 | 1.88e-03 |
| 9207 | aseg lh number HolesBeforeFixing | GCST90002630 | 1.88e-03 |
| 9208 | Triglyceride levels | GCST90278645 | 1.88e-03 |
| 9209 | AmygNuclei rh volume Whole-amygdala | GCST90002667 | 1.87e-03 |
| 9210 | MZB1/TNFRSF13B ratio | GCST90315509 | 1.87e-03 |
| 9211 | DFFA/SIRT2 ratio | GCST90314462 | 1.87e-03 |
| 9212 | SCGN levels | GCST90470544 | 1.87e-03 |
| 9213 | Vegetable intake (standard GWA) | GCST90267306 | 1.86e-03 |
| 9214 | Free cholesterol to total lipids ratio in small HDL | GCST90092949 | 1.86e-03 |
| 9215 | Insomnia | FING00000683 | 1.86e-03 |
| 9216 | GALNT7 levels | GCST90469299 | 1.86e-03 |
| 9217 | GRAP2/PLPBP ratio | GCST90314984 | 1.85e-03 |
| 9218 | QPCT levels | GCST90470401 | 1.85e-03 |
| 9219 | Cholesteryl esters in small LDL (UKB data field 23548) | GCST90269645 | 1.84e-03 |
| 9220 | Milk type used: Soy milk vs never have milk (UKB data field 1418) | GCST90132943 | 1.83e-03 |
| 9221 | High-density lipoprotein levels (MTAG) | GCST90179147 | 1.83e-03 |
| 9222 | SH2B3/TBL1X ratio | GCST90315841 | 1.82e-03 |
| 9223 | CD80 on monocyte | GCST90002039 | 1.82e-03 |
| 9224 | Hair colour (natural, before greying) - Dark brown | Sun exposure | UKBB00000297 | 1.81e-03 |
| 9225 | Saturated fatty acids to total fatty acids percentage | GCST90502697 | 1.81e-03 |
| 9226 | Soft cheese liking | GCST90094843 | 1.81e-03 |
| 9227 | Cholesterol in Large HDL | GCST90497709 | 1.81e-03 |
| 9228 | KIFBP/TACC3 ratio | GCST90315249 | 1.81e-03 |
| 9229 | AXIN1/CALCOCO1 ratio | GCST90313402 | 1.80e-03 |
| 9230 | NECTIN2/TNFRSF1A ratio | GCST90315532 | 1.80e-03 |
| 9231 | ITGA5 levels | GCST90469635 | 1.79e-03 |
| 9232 | HCLS1/TMSB10 ratio | GCST90315043 | 1.79e-03 |
| 9233 | Free cholesterol to total lipids in medium LDL percentage (UKB data field 23622) | GCST90269719 | 1.79e-03 |
| 9234 | Biological Father: Cancer, Skin | GCST90475240 | 1.78e-03 |
| 9235 | IL15/NCR1 ratio | GCST90315150 | 1.78e-03 |
| 9236 | PODXL2/SEZ6L ratio | GCST90315702 | 1.78e-03 |
| 9237 | SPON2 levels | GCST90470732 | 1.78e-03 |
| 9238 | Bone marrow fat fraction of lumbar vertebra 3 | GCST90652388 | 1.77e-03 |
| 9239 | SNAP29/TJAP1 ratio | GCST90315861 | 1.77e-03 |
| 9240 | Hepatic cancer | GCST90018638 | 1.77e-03 |
| 9241 | ADGRE5 levels | GCST90425484 | 1.77e-03 |
| 9242 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 1.76e-03 |
| 9243 | Disorders of iron metabolism (PheCode 275.1) | GCST90475743 | 1.76e-03 |
| 9244 | Triglyceride levels in small VLDL | GCST90132667 | 1.76e-03 |
| 9245 | CD302/CD99 ratio | GCST90313805 | 1.76e-03 |
| 9246 | SKAP2/VSIR ratio | GCST90315849 | 1.76e-03 |
| 9247 | Free Cholesterol to Total Lipids in Large VLDL percentage | GCST90498199 | 1.75e-03 |
| 9248 | NCK2 levels | GCST90470007 | 1.75e-03 |
| 9249 | ANPEP/CXADR ratio | GCST90313272 | 1.75e-03 |
| 9250 | UBA9475 sp002161235 abundance in stool | GCST90032635 | 1.75e-03 |
| 9251 | SUOX levels | GCST90470785 | 1.74e-03 |
| 9252 | ENG/NOTCH1 ratio | GCST90314648 | 1.74e-03 |
| 9253 | Total lipids in very small VLDL (UKB data field 23517) | GCST90269614 | 1.74e-03 |
| 9254 | Phospholipids in very small VLDL | GCST90500851 | 1.74e-03 |
| 9255 | DTI autoptx MD ifo r tract | GCST90385233 | 1.74e-03 |
| 9256 | FCRL1/TNFRSF13C ratio | GCST90314796 | 1.74e-03 |
| 9257 | Free Cholesterol in VLDL | GCST90500217 | 1.73e-03 |
| 9258 | RNASET2 levels | GCST90470481 | 1.73e-03 |
| 9259 | Body mass index (BMI, maximum, inv-normal transformed) | GCST90475153 | 1.73e-03 |
| 9260 | Total testosterone levels | GCST90012114 | 1.73e-03 |
| 9261 | RNF43 levels | GCST90470486 | 1.73e-03 |
| 9262 | Total lipid levels in medium HDL | GCST90092898 | 1.73e-03 |
| 9263 | Reaction time (standard GWA) | GCST90267296 | 1.73e-03 |
| 9264 | X-11787 levels | GCST90200465 | 1.73e-03 |
| 9265 | HPSE levels | GCST90469473 | 1.72e-03 |
| 9266 | Healthspan | GCST007406 | 1.72e-03 |
| 9267 | GPI levels | GCST90241269 | 1.71e-03 |
| 9268 | DLL1/NBL1 ratio | GCST90314496 | 1.71e-03 |
| 9269 | SEZ6L levels | GCST90470607 | 1.71e-03 |
| 9270 | Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581) | GCST90269678 | 1.70e-03 |
| 9271 | BAX levels | GCST90468424 | 1.70e-03 |
| 9272 | Extrapyramidal and movement disorders | FING00000527 | 1.69e-03 |
| 9273 | EDAR/SDC4 ratio | GCST90314585 | 1.69e-03 |
| 9274 | CLU levels | GCST90468793 | 1.68e-03 |
| 9275 | Cholesterol in Medium HDL | GCST90498492 | 1.68e-03 |
| 9276 | Takes medication for circulatory problem? | GCST90475218 | 1.68e-03 |
| 9277 | N-acetyl-1-methylhistidine levels | GCST90200690 | 1.68e-03 |
| 9278 | SNX2 levels | GCST90470701 | 1.67e-03 |
| 9279 | Dorsalgia | FING00000472 | 1.67e-03 |
| 9280 | CLEC1B levels | GCST90468768 | 1.67e-03 |
| 9281 | AHSP/CA2 ratio | GCST90313215 | 1.67e-03 |
| 9282 | CD84/GP6 ratio | GCST90313914 | 1.67e-03 |
| 9283 | CLEC1B/ITGB5 ratio | GCST90314094 | 1.66e-03 |
| 9284 | ERBIN/LYN ratio | GCST90314694 | 1.66e-03 |
| 9285 | Phospholipids to Total Lipids in IDL percentage | GCST90497644 | 1.66e-03 |
| 9286 | Annual healthcare cost | GCST90292604 | 1.66e-03 |
| 9287 | CPXM1/HBEGF ratio | GCST90314219 | 1.66e-03 |
| 9288 | VWC2L levels | GCST90471063 | 1.65e-03 |
| 9289 | Mean corpuscular haemoglobin concentration | Blood count | UKBB00000448 | 1.65e-03 |
| 9290 | ENO1 levels | GCST90469109 | 1.65e-03 |
| 9291 | Worry too long after an embarrassing experience | GCST006946 | 1.65e-03 |
| 9292 | FCGR2A/FCGR2B ratio | GCST90314793 | 1.64e-03 |
| 9293 | Cholesteryl ester levels in LDL | GCST90092884 | 1.64e-03 |
| 9294 | HAVCR2 levels | GCST90469432 | 1.64e-03 |
| 9295 | FUT8/SPARC ratio | GCST90314893 | 1.64e-03 |
| 9296 | Orange juice liking | GCST90094806 | 1.64e-03 |
| 9297 | Cholesteryl Esters in LDL | GCST90498363 | 1.64e-03 |
| 9298 | STK11/USP8 ratio | GCST90315892 | 1.63e-03 |
| 9299 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502168 | 1.63e-03 |
| 9300 | IL16 levels | GCST90469557 | 1.63e-03 |
| 9301 | Phosphatidylcholine-O_34:1_[M+H]1+/Phosphatidylcholine-P_34:0_[M+H]1+/Phosphatidylethanolamine-O_37:1_[M+H]1+ levels | GCST90060284 | 1.62e-03 |
| 9302 | C8B levels | GCST90468503 | 1.62e-03 |
| 9303 | CCL18 levels | GCST90468570 | 1.61e-03 |
| 9304 | Phospholipids to total lipids ratio in IDL | GCST90092840 | 1.61e-03 |
| 9305 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498287 | 1.61e-03 |
| 9306 | Estradiol levels | GCST90012105 | 1.61e-03 |
| 9307 | Epstein-Barr virus ZEBRA antibody levels | GCST90006901 | 1.60e-03 |
| 9308 | 5-hydroxyindole sulfate levels | GCST90200050 | 1.60e-03 |
| 9309 | Free thyroxine levels within normal range in pregnancy | GCST90435196 | 1.60e-03 |
| 9310 | 5,6-dihydrouridine levels | GCST90199767 | 1.60e-03 |
| 9311 | Docosahexaenoic acid levels | GCST90502243 | 1.60e-03 |
| 9312 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 1.60e-03 |
| 9313 | PAG1 levels | GCST90470147 | 1.59e-03 |
| 9314 | SERPINE2 levels | GCST90470597 | 1.59e-03 |
| 9315 | TREML1 levels | GCST90470961 | 1.59e-03 |
| 9316 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502051 | 1.59e-03 |
| 9317 | Free Cholesterol to Total Lipids in Medium LDL percentage | GCST90498784 | 1.59e-03 |
| 9318 | CFP levels | GCST90468731 | 1.59e-03 |
| 9319 | Parental longevity (both parents in top 10%) | GCST006698 | 1.59e-03 |
| 9320 | Obstructive chronic bronchitis (PheCode 496.21) | GCST90476030 | 1.58e-03 |
| 9321 | Diabetes mellitus (UKB data field 2443) | GCST90043627 | 1.58e-03 |
| 9322 | Thyrotoxicosis with or without goiter (PheCode 242) | GCST90475643 | 1.58e-03 |
| 9323 | KIR3DL1 levels | GCST90469687 | 1.58e-03 |
| 9324 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500539 | 1.58e-03 |
| 9325 | IDP dMRI ProbtrackX ICVF mcp | GCST90004391 | 1.57e-03 |
| 9326 | GRAP2/TYMP ratio | GCST90314990 | 1.57e-03 |
| 9327 | TACC3/TRIAP1 ratio | GCST90315901 | 1.57e-03 |
| 9328 | Triacylglycerol_56:7_[M+NH4]1+ levels | GCST90060551 | 1.56e-03 |
| 9329 | Sum neutrophil eosinophil counts | GCST004613 | 1.56e-03 |
| 9330 | Total lipids in small LDL | GCST90499656 | 1.56e-03 |
| 9331 | PGLYRP2 levels | GCST90470220 | 1.55e-03 |
| 9332 | SIGLEC8 levels | GCST90089886 | 1.55e-03 |
| 9333 | PROC levels | GCST90470335 | 1.55e-03 |
| 9334 | WFDC5 levels | GCST90089598 | 1.55e-03 |
| 9335 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502644 | 1.54e-03 |
| 9336 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500542 | 1.54e-03 |
| 9337 | CD55/CHI3L1 ratio | GCST90313845 | 1.54e-03 |
| 9338 | T1 FIRST volume R Puta | GCST90383995 | 1.54e-03 |
| 9339 | Blood cell traits latent factor 23 (white cell) | GCST90559265 | 1.54e-03 |
| 9340 | Trauma exposure | GCST009982 | 1.54e-03 |
| 9341 | Chicken liking | GCST90094732 | 1.53e-03 |
| 9342 | PRCP/SELE ratio | GCST90315726 | 1.53e-03 |
| 9343 | NPC2 levels | GCST90470068 | 1.53e-03 |
| 9344 | Attention deficit hyperactivity disorder (adjusted for age, sex) | GCST90275147 | 1.53e-03 |
| 9345 | DNMBP/TJAP1 ratio | GCST90314521 | 1.53e-03 |
| 9346 | Immature reticulocyte fraction | Blood count | UKBB00000355 | 1.53e-03 |
| 9347 | Chronic dermatitis due to solar radiation (PheCode 938.2) | GCST90476288 | 1.52e-03 |
| 9348 | PDZK1 levels | GCST90470203 | 1.52e-03 |
| 9349 | Honey liking | GCST90094782 | 1.52e-03 |
| 9350 | TNFRSF4 levels | GCST90470913 | 1.52e-03 |
| 9351 | Docosahexaenoic acid to total fatty acids percentage | GCST90501997 | 1.52e-03 |
| 9352 | Free cholesterol in large VLDL | GCST90498181 | 1.52e-03 |
| 9353 | Body mass index (MTAG) | GCST90179150 | 1.52e-03 |
| 9354 | EZR levels | GCST90469162 | 1.52e-03 |
| 9355 | CD244 levels | GCST90274771 | 1.51e-03 |
| 9356 | DOK2/PPP1R2 ratio | GCST90314537 | 1.51e-03 |
| 9357 | BMI and adiposity (confirmatory factor analysis Factor 7) | GCST90309342 | 1.51e-03 |
| 9358 | CCL5/TACC3 ratio | GCST90313707 | 1.51e-03 |
| 9359 | Myeloid white cell count | GCST004626 | 1.51e-03 |
| 9360 | DNAJB1/EIF4B ratio | GCST90314508 | 1.51e-03 |
| 9361 | MYH9 levels | GCST90469975 | 1.50e-03 |
| 9362 | Linoleic acid levels | GCST90502009 | 1.50e-03 |
| 9363 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502399 | 1.50e-03 |
| 9364 | Total lipids in large VLDL | GCST90498207 | 1.50e-03 |
| 9365 | Nonalcoholic steatohepatitis | FING00000879 | 1.49e-03 |
| 9366 | APOA1 levels | GCST90497122 | 1.49e-03 |
| 9367 | Long-standing illness, disability or infirmity | General health | UKBB00000409 | 1.49e-03 |
| 9368 | IDP dMRI TBSS FA Cingulum cingulate gyrus R | GCST90003911 | 1.49e-03 |
| 9369 | CXCL5/EDAR ratio | GCST90314349 | 1.48e-03 |
| 9370 | DTI TBSS FA Posterior thalamic radiation R | GCST90384408 | 1.48e-03 |
| 9371 | Granulocyte count | GCST004614 | 1.48e-03 |
| 9372 | Phospholipids in very small VLDL | GCST90500840 | 1.48e-03 |
| 9373 | Mean corpuscular hemoglobin variance | GCST90565693 | 1.47e-03 |
| 9374 | Diseases of white blood cells (PheCode 288) | GCST90475812 | 1.47e-03 |
| 9375 | Glycine levels | GCST90497316 | 1.47e-03 |
| 9376 | Ever Smoker | FING00000522 | 1.47e-03 |
| 9377 | rfMRI connectivity (ICA100 edge 605) | GCST90005458 | 1.47e-03 |
| 9378 | CD84/DAG1 ratio | GCST90313910 | 1.46e-03 |
| 9379 | Plasma 11beta-hydroxyandrosterone glucuronide levels in chronic kidney disease | GCST90264321 | 1.45e-03 |
| 9380 | Platelet count (UKB data field 30080) | GCST90468095 | 1.45e-03 |
| 9381 | DTI autoptx L3 ilf r tract | GCST90385208 | 1.45e-03 |
| 9382 | IPCEF1/SPARC ratio | GCST90315186 | 1.45e-03 |
| 9383 | IDP dMRI ProbtrackX OD slf l | GCST90004471 | 1.45e-03 |
| 9384 | CXCL1 levels | GCST90012019 | 1.45e-03 |
| 9385 | CD69/SNAP29 ratio | GCST90313887 | 1.45e-03 |
| 9386 | Cholesteryl esters to total lipids in medium LDL percentage (UKB data field 23621) | GCST90269718 | 1.45e-03 |
| 9387 | CD99L2 levels | GCST90468657 | 1.44e-03 |
| 9388 | Free Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498976 | 1.44e-03 |
| 9389 | Triglyceride levels (UKB data field 30870) | GCST90468106 | 1.44e-03 |
| 9390 | Total Lipids in HDL | GCST90497401 | 1.43e-03 |
| 9391 | Testosterone | Blood biochemistry | UKBB00000816 | 1.43e-03 |
| 9392 | Physical activity (Principal component 2) | GCST90061423 | 1.43e-03 |
| 9393 | Diacylglycerol_32:2_[M+H-H2O]1+ levels | GCST90060168 | 1.43e-03 |
| 9394 | CPXM1/SPARC ratio | GCST90314222 | 1.43e-03 |
| 9395 | EPHB4 levels | GCST90469132 | 1.43e-03 |
| 9396 | ZNRD2 levels | GCST90471103 | 1.42e-03 |
| 9397 | platelet count (maximum, inv-norm transformed) | GCST90476296 | 1.42e-03 |
| 9398 | DCXR/KYNU ratio | GCST90314438 | 1.42e-03 |
| 9399 | Reaction time (baseline) | GCST90565838 | 1.42e-03 |
| 9400 | Non-cancer illness code, self-reported - diabetes | Medical conditions | UKBB00000508 | 1.41e-03 |
| 9401 | BTN2A1 levels | GCST90468480 | 1.41e-03 |
| 9402 | FXN/METAP1D ratio | GCST90314897 | 1.41e-03 |
| 9403 | KLK8 levels | GCST90425492 | 1.41e-03 |
| 9404 | QC rfMRI cleaned inverse tSNR | GCST90006358 | 1.41e-03 |
| 9405 | T1 CAT volume L PlanumPolare | GCST90384086 | 1.40e-03 |
| 9406 | Treatment or medication use - metformin (UKB data field 20003_1140884600) | GCST90042245 | 1.40e-03 |
| 9407 | Obesity related asthma | FING00000897 | 1.39e-03 |
| 9408 | CD36 levels | GCST90468627 | 1.39e-03 |
| 9409 | Monocyte count | GCST90018747 | 1.39e-03 |
| 9410 | FAS levels | GCST90427702 | 1.39e-03 |
| 9411 | CEACAM5 levels | GCST90468696 | 1.38e-03 |
| 9412 | CHMP1A/EREG ratio | GCST90314048 | 1.38e-03 |
| 9413 | Tyrosine levels | GCST90500143 | 1.38e-03 |
| 9414 | Sum basophil neutrophil counts | GCST004620 | 1.38e-03 |
| 9415 | Cholesteryl Esters in IDL | GCST90497525 | 1.38e-03 |
| 9416 | CDCP1/IL18BP ratio | GCST90313937 | 1.38e-03 |
| 9417 | CGREF1 levels | GCST90468735 | 1.38e-03 |
| 9418 | Feeling fed-up | GCST006947 | 1.38e-03 |
| 9419 | AAGAB levels | GCST90617473 | 1.38e-03 |
| 9420 | PRTN3/RETN ratio | GCST90315734 | 1.38e-03 |
| 9421 | Saturated fatty acids to total fatty acids percentage | GCST90502700 | 1.37e-03 |
| 9422 | Rheumatoid arthritis | GCST90132223 | 1.37e-03 |
| 9423 | Time spent driving | Physical activity | UKBB00000818 | 1.37e-03 |
| 9424 | LDL cholesterol | GCST000759 | 1.37e-03 |
| 9425 | GSTA1/RBP5 ratio | GCST90314995 | 1.37e-03 |
| 9426 | ANPEP/NT5E ratio | GCST90313274 | 1.36e-03 |
| 9427 | Total concentration of lipoprotein particles (UKB data field 23427) | GCST90269524 | 1.36e-03 |
| 9428 | Number of sexual partners in opposite-sex sexual behavior | GCST90026480 | 1.36e-03 |
| 9429 | Volume of left medial nucleus | GCST90474976 | 1.36e-03 |
| 9430 | HBEGF/LAT2 ratio | GCST90315032 | 1.36e-03 |
| 9431 | Phospholipids to total lipids in very large HDL percentage (UKB data field 23629) | GCST90269726 | 1.34e-03 |
| 9432 | DTI TBSS L3 Posterior thalamic radiation R | GCST90384552 | 1.34e-03 |
| 9433 | PPP1R2/TACC3 ratio | GCST90315719 | 1.34e-03 |
| 9434 | Triglycerides in large VLDL | GCST90498267 | 1.34e-03 |
| 9435 | Hemoglobin concentration variance | GCST90565685 | 1.34e-03 |
| 9436 | ITGA6 levels | GCST90469636 | 1.34e-03 |
| 9437 | Cholesterol esters in very large HDL | GCST90500354 | 1.34e-03 |
| 9438 | DTI TBSS L3 External capsule L | GCST90384557 | 1.33e-03 |
| 9439 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502410 | 1.33e-03 |
| 9440 | Concentration of very small VLDL particles (UKB data field 23516) | GCST90269613 | 1.33e-03 |
| 9441 | Recurrent or chronic depression | FING00001243 | 1.33e-03 |
| 9442 | Recent feelings of tiredness or low energy | Depression | UKBB00000740 | 1.33e-03 |
| 9443 | Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] (PheCode 573.6) | GCST90476094 | 1.33e-03 |
| 9444 | MST1 levels | GCST90469952 | 1.32e-03 |
| 9445 | VAMP5 levels | GCST90471024 | 1.32e-03 |
| 9446 | Illnesses of father - Diabetes | Family history | UKBB00000341 | 1.32e-03 |
| 9447 | Pregnanediol-3-glucuronide levels | GCST90199917 | 1.32e-03 |
| 9448 | Glycine levels | GCST90200707 | 1.32e-03 |
| 9449 | Reticulocyte count | GCST90025972 | 1.32e-03 |
| 9450 | Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers) | FING00000766 | 1.31e-03 |
| 9451 | Mean time to correctly identify matches | Reaction time | UKBB00000453 | 1.31e-03 |
| 9452 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498125 | 1.31e-03 |
| 9453 | CLEC5A levels | GCST90468776 | 1.30e-03 |
| 9454 | platelet count (minimum, inv-norm transformed) | GCST90476302 | 1.30e-03 |
| 9455 | CLEC4G/MERTK ratio | GCST90314121 | 1.30e-03 |
| 9456 | CASP3/SERPINE1 ratio | GCST90313643 | 1.30e-03 |
| 9457 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) | GCST90499335 | 1.30e-03 |
| 9458 | Lager liking | GCST90094789 | 1.29e-03 |
| 9459 | Triglycerides in IDL | GCST90497671 | 1.29e-03 |
| 9460 | CCL25/PRSS27 ratio | GCST90313694 | 1.29e-03 |
| 9461 | Been in a confiding relationship as an adult | Traumatic events | UKBB00000088 | 1.29e-03 |
| 9462 | INSR levels | GCST90469623 | 1.29e-03 |
| 9463 | Gallstone disease | GCST90128518 | 1.29e-03 |
| 9464 | ENO3 levels | GCST90469111 | 1.28e-03 |
| 9465 | HippSubfield rh volume CA4-head | GCST90002704 | 1.28e-03 |
| 9466 | CCN2/SERPINB1 ratio | GCST90313715 | 1.28e-03 |
| 9467 | Red blood cell count | GCST90002403 | 1.28e-03 |
| 9468 | NOMO1 levels | GCST90470060 | 1.27e-03 |
| 9469 | PDGFA/USP8 ratio | GCST90315621 | 1.27e-03 |
| 9470 | DAG1/DBNL ratio | GCST90314372 | 1.27e-03 |
| 9471 | F-sweet food liking (derived food-liking factor) | GCST90094854 | 1.27e-03 |
| 9472 | CDH1/CST3 ratio | GCST90313946 | 1.27e-03 |
| 9473 | Neutrophil percentage of white cells variance | GCST90565701 | 1.27e-03 |
| 9474 | CEACAM8 levels | GCST90468698 | 1.26e-03 |
| 9475 | MINPP1 levels | GCST90241978 | 1.26e-03 |
| 9476 | Omega-6 fatty acids to total fatty acids percentage | GCST90502127 | 1.26e-03 |
| 9477 | Ximenoylcarnitine (C26:1) levels | GCST90200149 | 1.26e-03 |
| 9478 | Concentration of very large HDL particles | GCST90500436 | 1.26e-03 |
| 9479 | Phosphatidylglycerol (34:1) levels | GCST90025061 | 1.26e-03 |
| 9480 | Substance abuse (more control exclusions) | FING00001341 | 1.26e-03 |
| 9481 | High density lipoprotein cholesterol levels | GCST90278635 | 1.26e-03 |
| 9482 | TREM2 levels | GCST90470960 | 1.25e-03 |
| 9483 | DRG2/SEMA4D ratio | GCST90314554 | 1.25e-03 |
| 9484 | LDLR/PCSK9 ratio | GCST90315311 | 1.25e-03 |
| 9485 | ST3GAL1 levels | GCST90470752 | 1.25e-03 |
| 9486 | Phospholipids to total lipids in medium VLDL percentage (UKB data field 23594) | GCST90269691 | 1.25e-03 |
| 9487 | Cholesterol to Total Lipids in Large LDL percentage | GCST90497929 | 1.25e-03 |
| 9488 | LAT2 levels | GCST90469739 | 1.24e-03 |
| 9489 | Reticulocyte count (UKB data field 30250) | GCST90468100 | 1.24e-03 |
| 9490 | LZTFL1 levels | GCST90469834 | 1.24e-03 |
| 9491 | Stearoylcarnitine (C18) levels | GCST90199743 | 1.24e-03 |
| 9492 | Total cholesterol minus HDL-C levels | GCST90499130 | 1.24e-03 |
| 9493 | NRAC levels | GCST90617991 | 1.24e-03 |
| 9494 | RWDD1/SUMF2 ratio | GCST90315795 | 1.23e-03 |
| 9495 | Non-cancer illness year/age first occurred | Medical conditions | UKBB00000523 | 1.23e-03 |
| 9496 | LBR/MAD1L1 ratio | GCST90315295 | 1.23e-03 |
| 9497 | Neutrophil count | GCST004629 | 1.23e-03 |
| 9498 | Neutrophill percentage | Blood count | UKBB00000498 | 1.22e-03 |
| 9499 | Free cholesterol in very large VLDL | GCST90500575 | 1.22e-03 |
| 9500 | SUGT1/TBL1X ratio | GCST90315897 | 1.22e-03 |
| 9501 | Total cholines levels (UKB data field 23436) | GCST90269533 | 1.22e-03 |
| 9502 | Cognitive processing speed | GCST90446168 | 1.22e-03 |
| 9503 | F-coffee/alcohol liking (derived food-liking factor) | GCST90094737 | 1.22e-03 |
| 9504 | Erysipelas | FING00000518 | 1.22e-03 |
| 9505 | Phosphatidylcholine acyl-alkyl C36:5 levels | GCST90240073 | 1.21e-03 |
| 9506 | CASP3/LYN ratio | GCST90313635 | 1.21e-03 |
| 9507 | Total free cholesterol levels (UKB data field 23419) | GCST90269516 | 1.20e-03 |
| 9508 | SERPINE1 levels | GCST90470596 | 1.20e-03 |
| 9509 | Infective dermatitis | FING00000673 | 1.20e-03 |
| 9510 | Neuroticism | GCST003770 | 1.20e-03 |
| 9511 | CD79B/TNFRSF4 ratio | GCST90313903 | 1.19e-03 |
| 9512 | Epiandrosterone sulfate levels | GCST90199752 | 1.19e-03 |
| 9513 | Salad / raw vegetable intake | Diet | UKBB00000761 | 1.19e-03 |
| 9514 | FADD/LACTB2 ratio | GCST90314767 | 1.18e-03 |
| 9515 | Primary sclerosing cholangitis | GCST004030 | 1.18e-03 |
| 9516 | HBEGF/WWP2 ratio | GCST90315038 | 1.18e-03 |
| 9517 | EREG/TIMP3 ratio | GCST90314708 | 1.18e-03 |
| 9518 | CTSC/PLA2G15 ratio | GCST90314311 | 1.18e-03 |
| 9519 | Common executive function | GCST90162547 | 1.17e-03 |
| 9520 | Saturated fatty acids to total fatty acids percentage | GCST90502685 | 1.17e-03 |
| 9521 | Free Cholesterol to Total Lipids in IDL percentage | GCST90497576 | 1.17e-03 |
| 9522 | Linoleic acid levels | GCST90502311 | 1.17e-03 |
| 9523 | Cholesterol to Total Lipids in Small LDL percentage | GCST90499564 | 1.17e-03 |
| 9524 | ATOX1 levels | GCST90468385 | 1.17e-03 |
| 9525 | IMPA1 levels | GCST90469610 | 1.17e-03 |
| 9526 | Chest pain or discomfort | Chest pain | UKBB00000128 | 1.17e-03 |
| 9527 | Familial combined hyperlipidemia defined by Brunzell criteria | GCST90104003 | 1.17e-03 |
| 9528 | CLPS/PRSS2 ratio | GCST90314141 | 1.16e-03 |
| 9529 | Hidradenitis suppurativa | FING00000621 | 1.16e-03 |
| 9530 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500965 | 1.16e-03 |
| 9531 | Free cholesterol in very small VLDL | GCST90500774 | 1.16e-03 |
| 9532 | BCAM/PCDH17 ratio | GCST90313475 | 1.16e-03 |
| 9533 | LDL cholesterol levels | GCST90092883 | 1.15e-03 |
| 9534 | Shellfish liking | GCST90094838 | 1.15e-03 |
| 9535 | Triglycerides to total lipids in small HDL percentage (UKB data field 23648) | GCST90269745 | 1.15e-03 |
| 9536 | Globe artichoke liking | GCST90094771 | 1.15e-03 |
| 9537 | Lymphoid leukaemia (controls excluding all cancers) | FING00000741 | 1.15e-03 |
| 9538 | wg rh intensity-contrast insula | GCST90003861 | 1.15e-03 |
| 9539 | CST6/FABP9 ratio | GCST90314301 | 1.15e-03 |
| 9540 | Omega-6 fatty acids to total fatty acids percentage | GCST90502541 | 1.15e-03 |
| 9541 | Total Dihexosylceramide levels | GCST90025193 | 1.14e-03 |
| 9542 | ACVRL1/TNFRSF9 ratio | GCST90313160 | 1.14e-03 |
| 9543 | ATG4A/NSFL1C ratio | GCST90313368 | 1.14e-03 |
| 9544 | SMPD3 levels | GCST90470685 | 1.14e-03 |
| 9545 | Smoking status (weighted GWA) | GCST90267303 | 1.14e-03 |
| 9546 | PHOSPHO1 levels | GCST90470227 | 1.14e-03 |
| 9547 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498689 | 1.13e-03 |
| 9548 | FAM151A levels | GCST90242450 | 1.13e-03 |
| 9549 | NMNAT1 levels | GCST90470057 | 1.13e-03 |
| 9550 | Free cholesterol in very large HDL | GCST90500380 | 1.13e-03 |
| 9551 | KRT19 levels | GCST90469717 | 1.13e-03 |
| 9552 | ALB levels | GCST90269576 | 1.13e-03 |
| 9553 | Total lipids in small LDL (UKB data field 23545) | GCST90269642 | 1.13e-03 |
| 9554 | Fruit juice liking | GCST90094768 | 1.13e-03 |
| 9555 | KLK6 levels | GCST90469705 | 1.13e-03 |
| 9556 | IL1R1 levels | GCST90425563 | 1.13e-03 |
| 9557 | Neuroticism | GCST005232 | 1.13e-03 |
| 9558 | Triglycerides in VLDL (UKB data field 23408) | GCST90269505 | 1.12e-03 |
| 9559 | wg lh intensity-contrast rostralanteriorcingulate | GCST90003817 | 1.12e-03 |
| 9560 | HippSubfield lh volume Whole-hippocampal-head | GCST90002688 | 1.12e-03 |
| 9561 | RSPO1/SFRP1 ratio | GCST90315791 | 1.12e-03 |
| 9562 | Phospholipids in HDL | GCST90497437 | 1.12e-03 |
| 9563 | Fruit intake (weighted GWA) | GCST90267283 | 1.12e-03 |
| 9564 | Cholesteryl ester levels in large LDL | GCST90092858 | 1.12e-03 |
| 9565 | 1-palmitoylglycerophosphoethanolamine levels | GCST90243835 | 1.11e-03 |
| 9566 | Sphingomyelin_34:1_[M+H]1+ levels | GCST90060239 | 1.11e-03 |
| 9567 | CXCL11/VTA1 ratio | GCST90314337 | 1.11e-03 |
| 9568 | CD244/FCRL6 ratio | GCST90313765 | 1.11e-03 |
| 9569 | Triacylglycerol_58:7_[M+NH4]1+ levels | GCST90060564 | 1.11e-03 |
| 9570 | Total lipid levels in IDL | GCST90132633 | 1.11e-03 |
| 9571 | Cancer within the respiratory system (PheCode 165) | GCST90475571 | 1.10e-03 |
| 9572 | Glycated hemoglobin levels | GCST90002244 | 1.10e-03 |
| 9573 | Phospholipids in medium VLDL (UKB data field 23504) | GCST90269601 | 1.10e-03 |
| 9574 | Cholesteryl esters to total lipids in very large VLDL percentage (UKB data field 23586) | GCST90269683 | 1.10e-03 |
| 9575 | Juvenile rheumatoid arthirtis | FING00000706 | 1.10e-03 |
| 9576 | Red blood cell count | GCST90278641 | 1.10e-03 |
| 9577 | Ratio of polyunsaturated fatty acids to monounsaturated fatty acids | GCST90092940 | 1.10e-03 |
| 9578 | Feeling miserable | GCST006943 | 1.09e-03 |
| 9579 | Phospholipids to Total Lipids in Medium VLDL percentage | GCST90499044 | 1.09e-03 |
| 9580 | CDKN1A/YES1 ratio | GCST90313980 | 1.09e-03 |
| 9581 | Average diameter for LDL particles (UKB data field 23432) | GCST90269529 | 1.09e-03 |
| 9582 | Metabolic syndrome | GCST90444489 | 1.09e-03 |
| 9583 | ANXA3/ENO2 ratio | GCST90313281 | 1.08e-03 |
| 9584 | CD300C/GOLM2 ratio | GCST90313788 | 1.08e-03 |
| 9585 | Lichen sclerosus et atrophicus | FING00000723 | 1.08e-03 |
| 9586 | ICD10 O13: Gestational hypertension | GCST90454232 | 1.08e-03 |
| 9587 | ROBO1 levels | GCST90470489 | 1.08e-03 |
| 9588 | CXADR/MME ratio | GCST90314329 | 1.08e-03 |
| 9589 | DTI autoptx MD fmi tract | GCST90385231 | 1.08e-03 |
| 9590 | DNAJB1/STIP1 ratio | GCST90314513 | 1.08e-03 |
| 9591 | LCN2/S100A12 ratio | GCST90315309 | 1.08e-03 |
| 9592 | SCLY levels | GCST90470546 | 1.07e-03 |
| 9593 | Disorders of orbit | FING00000449 | 1.07e-03 |
| 9594 | Mean corpuscular hemoglobin concentration | GCST004605 | 1.07e-03 |
| 9595 | Saturated fatty acids levels | GCST90502671 | 1.07e-03 |
| 9596 | Raw carrot liking | GCST90094818 | 1.07e-03 |
| 9597 | Concentration of very large HDL particles | GCST90093011 | 1.06e-03 |
| 9598 | Ratio of monounsaturated fatty acids to total fatty acids | GCST90092929 | 1.06e-03 |
| 9599 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498583 | 1.06e-03 |
| 9600 | TIMP1 levels | GCST90470869 | 1.06e-03 |
| 9601 | wg rh intensity-contrast medialorbitofrontal | GCST90003840 | 1.06e-03 |
| 9602 | SERPING1 levels | GCST90470600 | 1.05e-03 |
| 9603 | CA5A levels | GCST90468514 | 1.05e-03 |
| 9604 | ANGPT1 levels | GCST90468300 | 1.05e-03 |
| 9605 | HEXIM1/TRIAP1 ratio | GCST90315054 | 1.05e-03 |
| 9606 | Facial wrinkles (under eye) | GCST90094903 | 1.04e-03 |
| 9607 | Degree of unsaturation | GCST90502748 | 1.04e-03 |
| 9608 | APP/TMSB10 ratio | GCST90313332 | 1.04e-03 |
| 9609 | Type 2 diabetes | GCST90086072 | 1.04e-03 |
| 9610 | CRKL/MANF ratio | GCST90314269 | 1.04e-03 |
| 9611 | Concentration of medium VLDL particles (UKB data field 23502) | GCST90269599 | 1.03e-03 |
| 9612 | aparc-a2009s lh area S-central | GCST90003341 | 1.03e-03 |
| 9613 | Gamma glutamyl transpeptidase | GCST90018734 | 1.03e-03 |
| 9614 | X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels | GCST90243619 | 1.03e-03 |
| 9615 | Reaction time | GCST006268 | 1.03e-03 |
| 9616 | CTSD levels | GCST90468910 | 1.03e-03 |
| 9617 | DTI TBSS L2 Tapetum L | GCST90384523 | 1.02e-03 |
| 9618 | DTI TBSS MD External capsule L | GCST90384605 | 1.02e-03 |
| 9619 | Back pain (PheCode 760) | GCST90476266 | 1.02e-03 |
| 9620 | DTI TBSS L2 Genu of corpus callosum | GCST90384478 | 1.02e-03 |
| 9621 | DPEP1 levels | GCST90469030 | 1.02e-03 |
| 9622 | Polymyalgia rheumatica | FING00001188 | 1.02e-03 |
| 9623 | Cholesteryl esters in large VLDL (UKB data field 23499) | GCST90269596 | 1.02e-03 |
| 9624 | LY6D/WFDC12 ratio | GCST90315346 | 1.02e-03 |
| 9625 | DLL1/NECTIN4 ratio | GCST90314497 | 1.02e-03 |
| 9626 | TRIM21 levels | GCST90470964 | 1.02e-03 |
| 9627 | REG1A/REG4 ratio | GCST90315762 | 1.01e-03 |
| 9628 | Prostate cancer | GCST90011808 | 1.01e-03 |
| 9629 | Total cholesterol levels | GCST90500022 | 1.00e-03 |
| 9630 | Lignoceroylcarnitine (C24) levels | GCST90200137 | 1.00e-03 |
| 9631 | MAD1L1/POLR2F ratio | GCST90315354 | 9.98e-04 |
| 9632 | Nonalcoholic fatty liver disease | FING00000878 | 9.90e-04 |
| 9633 | Spread type - Other type of spread/margarine | Diet | UKBB00000795 | 9.89e-04 |
| 9634 | Total lipid levels in large LDL | GCST90092862 | 9.89e-04 |
| 9635 | Bone marrow fat fraction of thoracic vertebra 10 | GCST90652382 | 9.87e-04 |
| 9636 | N-acetylphenylalanine levels | GCST90200677 | 9.87e-04 |
| 9637 | Medication use (drugs used in diabetes) | GCST90018761 | 9.86e-04 |
| 9638 | Number of fluid intelligence questions attempted within time limit | Fluid intelligence / reasoning | UKBB00000537 | 9.80e-04 |
| 9639 | Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585) | GCST90269682 | 9.77e-04 |
| 9640 | CD83/HAVCR2 ratio | GCST90313904 | 9.77e-04 |
| 9641 | wg lh intensity-contrast cuneus | GCST90003796 | 9.76e-04 |
| 9642 | VLDL cholesterol levels (UKB data field 23403) | GCST90269500 | 9.76e-04 |
| 9643 | Phospholipids to Total Lipids in Medium HDL percentage | GCST90498651 | 9.75e-04 |
| 9644 | Mucosal proctocolitis | FING00000841 | 9.75e-04 |
| 9645 | EBAG9/MITD1 ratio | GCST90314566 | 9.74e-04 |
| 9646 | Birth weight known - No | Early life factors | UKBB00000096 | 9.71e-04 |
| 9647 | Cooked vegetables consumption | GCST90132977 | 9.68e-04 |
| 9648 | Monounsaturated fatty acid levels | GCST90502359 | 9.65e-04 |
| 9649 | Number of days/week of moderate physical activity 10+ minutes | Physical activity | UKBB00000533 | 9.65e-04 |
| 9650 | THY1/TNFRSF21 ratio | GCST90315919 | 9.64e-04 |
| 9651 | Cholesterol levels in small LDL | GCST90092956 | 9.62e-04 |
| 9652 | IGFBP3 levels | GCST90102624 | 9.58e-04 |
| 9653 | CFH levels | GCST90468729 | 9.58e-04 |
| 9654 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498130 | 9.57e-04 |
| 9655 | PLXNB3/SNAP23 ratio | GCST90315693 | 9.57e-04 |
| 9656 | Triglycerides in medium HDL | GCST90498672 | 9.57e-04 |
| 9657 | STMN3 levels | GCST90242894 | 9.56e-04 |
| 9658 | Phosphatidylcholines levels (UKB data field 23437) | GCST90269534 | 9.55e-04 |
| 9659 | Triglycerides to Total Lipids in Small HDL percentage | GCST90499543 | 9.54e-04 |
| 9660 | Total lipid levels in LDL | GCST90092886 | 9.52e-04 |
| 9661 | HDL x anxiety interaction (2df test) | GCST90570665 | 9.51e-04 |
| 9662 | PSAPL1 levels | GCST90470350 | 9.50e-04 |
| 9663 | PTPN6 levels | GCST90470377 | 9.49e-04 |
| 9664 | PDGFA/PLA2G4A ratio | GCST90315615 | 9.49e-04 |
| 9665 | Biological Father: High cholesterol | GCST90475242 | 9.48e-04 |
| 9666 | ADIPOQ levels | GCST90293086 | 9.47e-04 |
| 9667 | CASP3/MESD ratio | GCST90313636 | 9.45e-04 |
| 9668 | TPSAB1 levels | GCST90470951 | 9.43e-04 |
| 9669 | Cholesterol levels in medium LDL | GCST90092904 | 9.43e-04 |
| 9670 | All influenza | FING00000064 | 9.39e-04 |
| 9671 | Degree of unsaturation | GCST90502231 | 9.37e-04 |
| 9672 | Frailty (Factor 1 - Limited Social Support) | GCST90624047 | 9.37e-04 |
| 9673 | REG1B levels | GCST90470448 | 9.37e-04 |
| 9674 | Cholesteryl Esters to Total Lipids in IDL percentage | GCST90497539 | 9.34e-04 |
| 9675 | Total triglycerides levels | GCST90500140 | 9.32e-04 |
| 9676 | IDP dMRI ProbtrackX ICVF ml r | GCST90004393 | 9.31e-04 |
| 9677 | 1-methylhistidine levels | GCST90199691 | 9.31e-04 |
| 9678 | CD200/CLEC4G ratio | GCST90313746 | 9.31e-04 |
| 9679 | Platelet count | Blood count | UKBB00000646 | 9.30e-04 |
| 9680 | Principal component-derived dietary pattern 8 | GCST90133013 | 9.29e-04 |
| 9681 | IDP T1 FAST ROIs V cerebellum VIIb | GCST90002576 | 9.27e-04 |
| 9682 | HMOX1 levels | GCST90469465 | 9.27e-04 |
| 9683 | Left-hemisphere salience/ventral attention network to hippocampus white-matter structural connectivity | GCST90302723 | 9.25e-04 |
| 9684 | Inflammatory bowel disease | GCST90432182 | 9.24e-04 |
| 9685 | Fed-up feelings | Mental health | UKBB00000242 | 9.23e-04 |
| 9686 | DTI TBSS L3 Superior cerebellar peduncle R | GCST90384536 | 9.23e-04 |
| 9687 | Type 1 diabetes, definitions combined | FING00001380 | 9.22e-04 |
| 9688 | Usual side of head for mobile phone use - Right | Electronic device use | UKBB00000890 | 9.21e-04 |
| 9689 | Total lipids in large LDL | GCST90498021 | 9.19e-04 |
| 9690 | DTI autoptx FA ifo r tract | GCST90385125 | 9.19e-04 |
| 9691 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90500905 | 9.13e-04 |
| 9692 | Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428) | GCST90132951 | 9.12e-04 |
| 9693 | UMOD levels | GCST90471009 | 9.11e-04 |
| 9694 | TGFBI/VASN ratio | GCST90315915 | 9.09e-04 |
| 9695 | SELP levels | GCST90470569 | 9.09e-04 |
| 9696 | Other reaction to severe stress, and adjustment disorders | FING00001092 | 9.08e-04 |
| 9697 | Total esterified cholesterol levels | GCST90500034 | 9.08e-04 |
| 9698 | Cholesteryl esters in VLDL (UKB data field 23416) | GCST90269513 | 9.06e-04 |
| 9699 | YTHDF3 levels | GCST90471091 | 9.06e-04 |
| 9700 | PTPRF/SDC1 ratio | GCST90315752 | 9.05e-04 |
| 9701 | Insomnia (standard GWA) | GCST90267286 | 9.04e-04 |
| 9702 | Mouth/teeth dental problems - Bleeding gums | Mouth | UKBB00000485 | 9.03e-04 |
| 9703 | ICD10 C61: Malignant neoplasm of prostate | GCST90043894 | 9.03e-04 |
| 9704 | TNFRSF13C levels | GCST90470906 | 9.02e-04 |
| 9705 | PFKFB2/SRP14 ratio | GCST90315650 | 8.99e-04 |
| 9706 | Other systemic involvement of connective tissue (FG) | FING00001116 | 8.99e-04 |
| 9707 | Time spent outdoors in winter | Sun exposure | UKBB00000819 | 8.99e-04 |
| 9708 | Multiple sclerosis | GCST90475833 | 8.95e-04 |
| 9709 | Cholesterol levels in very large HDL | GCST90500310 | 8.95e-04 |
| 9710 | TNFRSF1A/TNFRSF1B ratio | GCST90315937 | 8.94e-04 |
| 9711 | Total cholesterol levels (UKB data field 23400) | GCST90269497 | 8.92e-04 |
| 9712 | BGN levels | GCST90468441 | 8.88e-04 |
| 9713 | Migraine with aura | FING00000819 | 8.86e-04 |
| 9714 | Treatment/medication code - allopurinol | Medications | UKBB00000839 | 8.86e-04 |
| 9715 | Concentration of medium VLDL particles | GCST90499017 | 8.80e-04 |
| 9716 | F-acquired taste liking (derived food-liking factor) | GCST90094791 | 8.80e-04 |
| 9717 | ENO2/PRSS27 ratio | GCST90314666 | 8.80e-04 |
| 9718 | Actinic keratosis | FING00000013 | 8.79e-04 |
| 9719 | KDM3A levels | GCST90469671 | 8.79e-04 |
| 9720 | Treatment speciality of consultant (recoded) - General medicine | Summary Administration | UKBB00000832 | 8.76e-04 |
| 9721 | F-fish liking (derived food-liking factor) | GCST90094762 | 8.76e-04 |
| 9722 | ITGB1BP2/WASF1 ratio | GCST90315224 | 8.73e-04 |
| 9723 | Other localized connective tissue disorders | FING00001066 | 8.71e-04 |
| 9724 | Liver volume | GCST90016666 | 8.71e-04 |
| 9725 | PLG levels | GCST90470257 | 8.70e-04 |
| 9726 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500943 | 8.69e-04 |
| 9727 | Suggestive for eosinophilic asthma | FING00001344 | 8.68e-04 |
| 9728 | Sphingomyelins levels | GCST90499972 | 8.68e-04 |
| 9729 | Current employment status - Unable to work because of sickness or disability | Employment | UKBB00000160 | 8.64e-04 |
| 9730 | RILP/RWDD1 ratio | GCST90315778 | 8.63e-04 |
| 9731 | KIRREL2/PLA2G1B ratio | GCST90315251 | 8.60e-04 |
| 9732 | Do you smoke now? | GCST90476389 | 8.59e-04 |
| 9733 | Other obstetric trauma | FING00001082 | 8.57e-04 |
| 9734 | Cognition and processing speed (confirmatory factor analysis Factor 34) | GCST90309368 | 8.57e-04 |
| 9735 | CCL3 levels | GCST90012055 | 8.56e-04 |
| 9736 | Concentration of VLDL particles (UKB data field 23428) | GCST90269525 | 8.56e-04 |
| 9737 | Polyunsaturated fatty acid levels | GCST90502623 | 8.56e-04 |
| 9738 | LGALS9/SIGLEC1 ratio | GCST90315323 | 8.56e-04 |
| 9739 | Treatment/medication code - simvastatin | Medications | UKBB00000859 | 8.52e-04 |
| 9740 | Worry too long after embarrassment | Mental health | UKBB00000922 | 8.52e-04 |
| 9741 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 8.49e-04 |
| 9742 | APOA1 levels | GCST90497119 | 8.45e-04 |
| 9743 | PAPPA levels | GCST90470157 | 8.45e-04 |
| 9744 | LAT/SPARC ratio | GCST90315288 | 8.44e-04 |
| 9745 | Total lipids in IDL | GCST90497601 | 8.41e-04 |
| 9746 | DBI/MESD ratio | GCST90314409 | 8.40e-04 |
| 9747 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499109 | 8.40e-04 |
| 9748 | Triglycerides in very small VLDL | GCST90500873 | 8.39e-04 |
| 9749 | Types of physical activity in last 4 weeks - Light DIY (eg: pruning, watering the lawn) | Physical activity | UKBB00000871 | 8.39e-04 |
| 9750 | ICAM3/TNFRSF13B ratio | GCST90315124 | 8.39e-04 |
| 9751 | CCN2/TPP1 ratio | GCST90313718 | 8.38e-04 |
| 9752 | Radiculopathy | FING00001238 | 8.36e-04 |
| 9753 | ADH4 levels | GCST90468244 | 8.35e-04 |
| 9754 | RHOC levels | GCST90470467 | 8.35e-04 |
| 9755 | Mental and behavioural disorders due to use of other stimulants, including caffeine | FING00000811 | 8.35e-04 |
| 9756 | Lysophosphatidylcholine (26:0) [sn2] levels | GCST90024189 | 8.34e-04 |
| 9757 | Histidine levels | GCST90497479 | 8.33e-04 |
| 9758 | CA5A/GSTA1 ratio | GCST90313591 | 8.33e-04 |
| 9759 | CD101 levels | GCST90468596 | 8.31e-04 |
| 9760 | GLOD4/MIF ratio | GCST90314939 | 8.28e-04 |
| 9761 | Cholesteryl Esters in Large HDL | GCST90497751 | 8.27e-04 |
| 9762 | Triglycerides in medium LDL | GCST90498864 | 8.22e-04 |
| 9763 | Venous thromboembolism | FING00001427 | 8.20e-04 |
| 9764 | Coffee intake | Diet | UKBB00000138 | 8.20e-04 |
| 9765 | CCL2/CCL7 ratio | GCST90313696 | 8.19e-04 |
| 9766 | Alcohol dependence | FING00000050 | 8.19e-04 |
| 9767 | ATP5IF1/F2R ratio | GCST90313384 | 8.18e-04 |
| 9768 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T81 | ECGU000081 | 8.18e-04 |
| 9769 | 3,4-dihydroxybutyrate levels | GCST90199816 | 8.17e-04 |
| 9770 | CLEC1B/PPP1R2 ratio | GCST90314101 | 8.15e-04 |
| 9771 | CLEC1B/LBR ratio | GCST90314095 | 8.15e-04 |
| 9772 | TNFAIP8 levels | GCST90470898 | 8.14e-04 |
| 9773 | Concentration of very large HDL particles | GCST90500431 | 8.13e-04 |
| 9774 | Nervous feelings | Mental health | UKBB00000495 | 8.11e-04 |
| 9775 | Phospholipids in HDL | GCST90497430 | 8.11e-04 |
| 9776 | ATP5IF1/FIS1 ratio | GCST90313385 | 8.09e-04 |
| 9777 | Phospholipids in medium VLDL | GCST90499025 | 8.08e-04 |
| 9778 | Methods of admission to hospital (recoded) - Elective admission: Booked | Summary Administration | UKBB00000461 | 8.07e-04 |
| 9779 | FOLH1 levels | GCST90425661 | 8.06e-04 |
| 9780 | Total phospholipids in lipoprotein particles (UKB data field 23411) | GCST90269508 | 8.04e-04 |
| 9781 | CD27/TGFBR2 ratio | GCST90313776 | 8.04e-04 |
| 9782 | ASGR2 levels | GCST90468376 | 8.01e-04 |
| 9783 | X-24328 levels | GCST90200624 | 7.99e-04 |
| 9784 | IL1RL2 levels | GCST90469575 | 7.98e-04 |
| 9785 | AXIN1/CDKN1A ratio | GCST90313403 | 7.98e-04 |
| 9786 | Physical activity (Total log acceleration 12am-2am) | GCST90061409 | 7.97e-04 |
| 9787 | Multiple myeloma | GCST90624747 | 7.97e-04 |
| 9788 | Docosahexaenoic acid levels | GCST90502242 | 7.97e-04 |
| 9789 | Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523 | FING00000304 | 7.95e-04 |
| 9790 | Tea consumption | GCST90096926 | 7.93e-04 |
| 9791 | Acute bronchitis | FING00000021 | 7.92e-04 |
| 9792 | Triglycerides to Total Lipids in Small VLDL percentage | GCST90499934 | 7.92e-04 |
| 9793 | VSIG2 levels | GCST90471051 | 7.91e-04 |
| 9794 | CD58/LTBR ratio | GCST90313851 | 7.90e-04 |
| 9795 | wg rh intensity-contrast bankssts | GCST90003828 | 7.89e-04 |
| 9796 | Gout, unspecified | FING00000589 | 7.89e-04 |
| 9797 | Visceral adipose tissue volume | GCST90016671 | 7.88e-04 |
| 9798 | Cholesterol to total lipids in IDL percentage (UKB data field 23610) | GCST90269707 | 7.88e-04 |
| 9799 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500398 | 7.87e-04 |
| 9800 | CDKN2D/TACC3 ratio | GCST90313992 | 7.85e-04 |
| 9801 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500565 | 7.84e-04 |
| 9802 | Seropositive rheumatoid arthritis, wide | FING00001298 | 7.84e-04 |
| 9803 | Otitis media (PheCode 381.1) | GCST90475903 | 7.83e-04 |
| 9804 | Use of sun/uv protection | Sun exposure | UKBB00000887 | 7.81e-04 |
| 9805 | CCDC50 levels | GCST90468561 | 7.79e-04 |
| 9806 | Free cholesterol in large LDL | GCST90497981 | 7.78e-04 |
| 9807 | SUSD5 levels | GCST90470789 | 7.76e-04 |
| 9808 | Principal component-derived dietary pattern 18 | GCST90133023 | 7.75e-04 |
| 9809 | ACE2/MME ratio | GCST90313154 | 7.74e-04 |
| 9810 | SNRPB2 levels | GCST90470697 | 7.73e-04 |
| 9811 | Phospholipids to total lipids in IDL percentage (UKB data field 23609) | GCST90269706 | 7.70e-04 |
| 9812 | Sphingomyelin levels | GCST90092982 | 7.69e-04 |
| 9813 | Time to complete round | Pairs matching | UKBB00000822 | 7.68e-04 |
| 9814 | CRACR2A/IRAG2 ratio | GCST90314227 | 7.65e-04 |
| 9815 | SPOCK2 levels | GCST90242987 | 7.65e-04 |
| 9816 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 7.64e-04 |
| 9817 | Total phospholipid levels in lipoprotein particles | GCST90500110 | 7.63e-04 |
| 9818 | F-savoury food liking (derived food-liking factor) | GCST90094833 | 7.62e-04 |
| 9819 | RNASEH2A levels | GCST90470480 | 7.60e-04 |
| 9820 | BCAM/CLEC14A ratio | GCST90313470 | 7.60e-04 |
| 9821 | Ratio of triglycerides to phosphoglycerides | GCST90092983 | 7.60e-04 |
| 9822 | SIAE levels | GCST90470629 | 7.57e-04 |
| 9823 | ALCAM levels | GCST90468279 | 7.55e-04 |
| 9824 | Other disorders of skin and subcutaneous tissue | FING00001035 | 7.54e-04 |
| 9825 | IDP dMRI TBSS L1 Body of corpus callosum | GCST90004078 | 7.50e-04 |
| 9826 | Squamous cell carcinoma (MTAG) | GCST90137412 | 7.49e-04 |
| 9827 | TNFSF13B levels | GCST90470920 | 7.47e-04 |
| 9828 | IL18R1 levels | GCST90469565 | 7.47e-04 |
| 9829 | FAM3D levels | GCST90469188 | 7.46e-04 |
| 9830 | Phosphoglycerides levels | GCST90092938 | 7.45e-04 |
| 9831 | Phospholipids in large VLDL | GCST90498247 | 7.44e-04 |
| 9832 | IDO1 levels | GCST90241490 | 7.43e-04 |
| 9833 | Cancer of bronchus; lung (PheCode 165.1) | GCST90475573 | 7.43e-04 |
| 9834 | Cholesteryl Esters to Total Lipids in Large LDL percentage | GCST90497969 | 7.42e-04 |
| 9835 | CD164 levels | GCST90468602 | 7.42e-04 |
| 9836 | GLOD4/S100A4 ratio | GCST90314944 | 7.40e-04 |
| 9837 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502571 | 7.40e-04 |
| 9838 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500397 | 7.38e-04 |
| 9839 | CNPY4/MESD ratio | GCST90314152 | 7.38e-04 |
| 9840 | RTN4IP1 levels | GCST90470507 | 7.37e-04 |
| 9841 | Principal component-derived dietary pattern 17 | GCST90133022 | 7.35e-04 |
| 9842 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 7.31e-04 |
| 9843 | Physical activity (confirmatory factor analysis Factor 23) | GCST90309357 | 7.30e-04 |
| 9844 | Depression medications | FING00000399 | 7.30e-04 |
| 9845 | DIABLO/DOK2 ratio | GCST90314464 | 7.29e-04 |
| 9846 | Free cholesterol in small HDL | GCST90499411 | 7.28e-04 |
| 9847 | HGF levels | GCST90469449 | 7.28e-04 |
| 9848 | Friendships satisfaction | Mental health | UKBB00000273 | 7.25e-04 |
| 9849 | Total lipids in VLDL (UKB data field 23424) | GCST90269521 | 7.24e-04 |
| 9850 | Happiness | Mental health | UKBB00000305 | 7.23e-04 |
| 9851 | Prescriptions - alpha1-antagonist|alpha blocker | UKBB00000659 | 7.21e-04 |
| 9852 | Cholesterol esters in very small VLDL | GCST90500749 | 7.21e-04 |
| 9853 | Malignant neoplasm of bronchus and lung | Malignant neoplasms of respiratory and intrathoracic organs | UKBB00000425 | 7.20e-04 |
| 9854 | FUT8 levels | GCST90469281 | 7.20e-04 |
| 9855 | Cholesterol to Total Lipids in IDL percentage | GCST90497511 | 7.19e-04 |
| 9856 | Monocyte percentage (UKB data field 30190) | GCST90468091 | 7.18e-04 |
| 9857 | Phospholipids in very large HDL (UKB data field 23553) | GCST90269650 | 7.17e-04 |
| 9858 | IGFBPL1 levels | GCST90179323 | 7.14e-04 |
| 9859 | CCN2 levels | GCST90468588 | 7.13e-04 |
| 9860 | CDNF levels | GCST90468686 | 7.13e-04 |
| 9861 | EPPK1 levels | GCST90469137 | 7.12e-04 |
| 9862 | Cod liking | GCST90094736 | 7.11e-04 |
| 9863 | Illnesses of father - Lung cancer | Family history | UKBB00000344 | 7.11e-04 |
| 9864 | N-acetyltaurine levels | GCST90199967 | 7.09e-04 |
| 9865 | RLN2 levels | GCST90470474 | 7.07e-04 |
| 9866 | Nontoxic multinodular goitre | FING00000888 | 7.05e-04 |
| 9867 | Platelet count | GCST90002402 | 7.04e-04 |
| 9868 | Metabolic disorders | FING00000816 | 7.04e-04 |
| 9869 | PLA2G4A/SPINT2 ratio | GCST90315671 | 7.02e-04 |
| 9870 | Omega-6 fatty acid levels | GCST90502519 | 7.01e-04 |
| 9871 | Cholesterol levels in very small VLDL | GCST90500712 | 6.98e-04 |
| 9872 | FCRL5/LY96 ratio | GCST90314803 | 6.97e-04 |
| 9873 | CRACR2A/DNMBP ratio | GCST90314226 | 6.96e-04 |
| 9874 | Continuous positive airway pressure | FING00000349 | 6.96e-04 |
| 9875 | ERBB3/IL1R2 ratio | GCST90314689 | 6.96e-04 |
| 9876 | Alcohol use disorder, Swedish definition | FING00000053 | 6.95e-04 |
| 9877 | CXCL10 levels | GCST90274780 | 6.93e-04 |
| 9878 | CD72 levels | GCST90468646 | 6.92e-04 |
| 9879 | Guilty feelings | Mental health | UKBB00000291 | 6.91e-04 |
| 9880 | LTBP3 levels | GCST90469815 | 6.86e-04 |
| 9881 | MAP4K5/STAMBP ratio | GCST90315382 | 6.84e-04 |
| 9882 | MITD1/RHOC ratio | GCST90315453 | 6.84e-04 |
| 9883 | DNA methylation Hannum age acceleration | GCST90014289 | 6.81e-04 |
| 9884 | Serum copper levels | GCST90100524 | 6.81e-04 |
| 9885 | Total lipids in very large HDL (UKB data field 23552) | GCST90269649 | 6.79e-04 |
| 9886 | Diacylglycerol_34:3_[M+H-H2O]1+ levels | GCST90060177 | 6.79e-04 |
| 9887 | HMBS/PSMG3 ratio | GCST90315064 | 6.77e-04 |
| 9888 | Total lipids in small VLDL | GCST90499849 | 6.77e-04 |
| 9889 | ANXA3/ANXA4 ratio | GCST90313278 | 6.75e-04 |
| 9890 | CDH5/LGALS4 ratio | GCST90313956 | 6.75e-04 |
| 9891 | Phosphatidylcholine-2O_32:0_[M+H]1+ levels | GCST90060244 | 6.74e-04 |
| 9892 | Phospholipids in large HDL | GCST90497847 | 6.73e-04 |
| 9893 | REST UKBBICA NODEamps25 0009 | GCST90385492 | 6.73e-04 |
| 9894 | Financial situation satisfaction | Mental health | UKBB00000249 | 6.72e-04 |
| 9895 | Other disorders of patella | FING00001032 | 6.71e-04 |
| 9896 | Spread type - Butter/spreadable butter | Diet | UKBB00000793 | 6.70e-04 |
| 9897 | Cholesterol to total lipids in small VLDL percentage (UKB data field 23600) | GCST90269697 | 6.69e-04 |
| 9898 | DNMBP/TBC1D5 ratio | GCST90314519 | 6.69e-04 |
| 9899 | Nummular dermatitis | FING00000893 | 6.69e-04 |
| 9900 | Usual side of head for mobile phone use - Equally left and right | Electronic device use | UKBB00000888 | 6.67e-04 |
| 9901 | TNFRSF13B/TNFRSF13C ratio | GCST90315931 | 6.66e-04 |
| 9902 | Mean diameter of VLDL particles | GCST90132734 | 6.66e-04 |
| 9903 | CDH3/TNFRSF21 ratio | GCST90313953 | 6.66e-04 |
| 9904 | KLK15 levels | GCST90469701 | 6.64e-04 |
| 9905 | Free Cholesterol to Total Lipids in Large LDL percentage | GCST90498000 | 6.63e-04 |
| 9906 | Cholesteryl Esters in Large LDL | GCST90497955 | 6.62e-04 |
| 9907 | Completion of the aide-memoire | GCST90012793 | 6.62e-04 |
| 9908 | Primary biliary cholangitis (PBC) | FING00001211 | 6.61e-04 |
| 9909 | BTN2A1/IFNGR1 ratio | GCST90313543 | 6.60e-04 |
| 9910 | Platelet count | GCST004603 | 6.59e-04 |
| 9911 | WARS levels | GCST90471066 | 6.59e-04 |
| 9912 | CD244/TREML2 ratio | GCST90313767 | 6.59e-04 |
| 9913 | Saturated fatty acids to total fatty acids percentage | GCST90502199 | 6.58e-04 |
| 9914 | ENTPD2 levels | GCST90469120 | 6.57e-04 |
| 9915 | Total concentration of lipoprotein particles | GCST90092990 | 6.57e-04 |
| 9916 | Triglycerides to total lipids in IDL percentage (UKB data field 23613) | GCST90269710 | 6.56e-04 |
| 9917 | IDP dMRI ProbtrackX OD slf r | GCST90004472 | 6.53e-04 |
| 9918 | PCDH12 levels | GCST90470168 | 6.49e-04 |
| 9919 | Phospholipid levels in IDL | GCST90092839 | 6.49e-04 |
| 9920 | 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels | GCST90199854 | 6.46e-04 |
| 9921 | BCL2L11/VASH1 ratio | GCST90313485 | 6.46e-04 |
| 9922 | UPB1 levels | GCST90471013 | 6.44e-04 |
| 9923 | Concentration of HDL particles | GCST90497406 | 6.43e-04 |
| 9924 | HSIL lesion of the cervix uteri, vagina or vulva | FING00000625 | 6.43e-04 |
| 9925 | MDK levels | GCST90469877 | 6.42e-04 |
| 9926 | Kiwi liking | GCST90094788 | 6.41e-04 |
| 9927 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500508 | 6.41e-04 |
| 9928 | Depressive episode | Mood [affective] disorders | UKBB00000166 | 6.39e-04 |
| 9929 | 2s,3R-dihydroxybutyrate levels | GCST90199882 | 6.38e-04 |
| 9930 | Cholesterol esters in very large HDL | GCST90500344 | 6.36e-04 |
| 9931 | HLAE/IL15 ratio | GCST90315061 | 6.36e-04 |
| 9932 | CD69/SCARF1 ratio | GCST90313885 | 6.36e-04 |
| 9933 | Types of physical activity in last 4 weeks - Strenuous sports | Physical activity | UKBB00000874 | 6.34e-04 |
| 9934 | Free Cholesterol to Total Lipids in Large LDL percentage | GCST90498007 | 6.34e-04 |
| 9935 | BCL2L11/RAB6A ratio | GCST90313484 | 6.32e-04 |
| 9936 | Total concentration of branched-chain amino acids (leucine + isoleucine + valine) | GCST90092984 | 6.32e-04 |
| 9937 | Triglycerides in very large HDL | GCST90500481 | 6.31e-04 |
| 9938 | CRIM1 levels | GCST90468863 | 6.29e-04 |
| 9939 | Body mass index (BMI) | Impedance measures | UKBB00000104 | 6.28e-04 |
| 9940 | Saturated fatty acids levels | GCST90502194 | 6.27e-04 |
| 9941 | Docosahexaenoic acid levels | GCST90501978 | 6.26e-04 |
| 9942 | Cancer code, self-reported: prostate cancer (UKB data field 20001_1044) | GCST90041905 | 6.26e-04 |
| 9943 | T1 FreeSurfer DK lh MeanThickness thickness | GCST90385656 | 6.25e-04 |
| 9944 | Urine dimethylglycine levels in chronic kidney disease | GCST90265045 | 6.25e-04 |
| 9945 | CD28 levels | GCST90468616 | 6.24e-04 |
| 9946 | HippSubfield rh volume subiculum-head | GCST90002693 | 6.22e-04 |
| 9947 | Type 1 diabetes (PheCode 250.1) | GCST90475661 | 6.21e-04 |
| 9948 | MME levels | GCST90469914 | 6.20e-04 |
| 9949 | Alcohol usually taken with meals | Alcohol | UKBB00000025 | 6.19e-04 |
| 9950 | Cholesteryl esters to total lipids in IDL percentage (UKB data field 23611) | GCST90269708 | 6.19e-04 |
| 9951 | Phospholipids in small VLDL (UKB data field 23511) | GCST90269608 | 6.19e-04 |
| 9952 | Principal component-derived dietary pattern 20 | GCST90133025 | 6.19e-04 |
| 9953 | LDLR/MEGF9 ratio | GCST90315310 | 6.17e-04 |
| 9954 | DNAJB1/SIRT2 ratio | GCST90314511 | 6.17e-04 |
| 9955 | APOB levels | GCST90497130 | 6.16e-04 |
| 9956 | Acute alcohol intoxication | FING00000014 | 6.16e-04 |
| 9957 | DTI TBSS FA External capsule L | GCST90384413 | 6.15e-04 |
| 9958 | Diseases of male genital organs | FING00000426 | 6.15e-04 |
| 9959 | Phospholipids in very large HDL | GCST90500451 | 6.14e-04 |
| 9960 | CD300C/HAVCR2 ratio | GCST90313789 | 6.12e-04 |
| 9961 | IL1B levels | GCST90469570 | 6.10e-04 |
| 9962 | LGALS4/TIE1 ratio | GCST90315316 | 6.10e-04 |
| 9963 | Liver enzyme levels (alkaline phosphatase) | GCST90013406 | 6.09e-04 |
| 9964 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501068 | 6.08e-04 |
| 9965 | Phospholipid levels in medium LDL | GCST90092912 | 6.07e-04 |
| 9966 | Total cholesterol levels | GCST90018754 | 6.07e-04 |
| 9967 | Cholesteryl ester levels in small VLDL | GCST90092970 | 6.06e-04 |
| 9968 | KLK6/PTPRN2 ratio | GCST90315256 | 6.06e-04 |
| 9969 | C9 Carnitine levels in chronic kidney disease | GCST90257682 | 6.05e-04 |
| 9970 | Mean platelet volume during first trimester of pregnancy | GCST90302229 | 6.04e-04 |
| 9971 | BA-exvivo lh area BA4p | GCST90003212 | 6.03e-04 |
| 9972 | Phospholipids to Total Lipids in Small VLDL percentage | GCST90499895 | 6.03e-04 |
| 9973 | CDH1/CDH17 ratio | GCST90313945 | 6.01e-04 |
| 9974 | SIT1 levels | GCST90470644 | 6.01e-04 |
| 9975 | HSIL lesion of the cervix uteri | FING00000624 | 6.01e-04 |
| 9976 | Blood cell traits latent factor 2 (red cell) | GCST90559244 | 6.00e-04 |
| 9977 | Chromatiales abundance in stool | GCST90032318 | 6.00e-04 |
| 9978 | CDSN/NECTIN4 ratio | GCST90313998 | 5.98e-04 |
| 9979 | Phospholipid levels in large LDL | GCST90132648 | 5.98e-04 |
| 9980 | Triglycerides in large HDL | GCST90497888 | 5.97e-04 |
| 9981 | STX8/USP8 ratio | GCST90315896 | 5.96e-04 |
| 9982 | CCL3 levels | GCST90468582 | 5.94e-04 |
| 9983 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502566 | 5.94e-04 |
| 9984 | CEACAM1 levels | GCST90468692 | 5.93e-04 |
| 9985 | CLPS/PLA2G1B ratio | GCST90314140 | 5.93e-04 |
| 9986 | Syncope and collapse | symptoms | UKBB00000801 | 5.92e-04 |
| 9987 | TDP1 levels | GCST90470826 | 5.91e-04 |
| 9988 | CCL28 levels | GCST90468580 | 5.91e-04 |
| 9989 | T1 CAT volume L CingulateGyrusanteriordivision | GCST90384056 | 5.90e-04 |
| 9990 | Statin medication | FING00001331 | 5.86e-04 |
| 9991 | MANF/NCK2 ratio | GCST90315359 | 5.86e-04 |
| 9992 | NUDT5/SERPINB1 ratio | GCST90315581 | 5.86e-04 |
| 9993 | CD163/MARCO ratio | GCST90313737 | 5.84e-04 |
| 9994 | Concentration of medium HDL particles | GCST90498617 | 5.84e-04 |
| 9995 | CDSN levels | GCST90468688 | 5.84e-04 |
| 9996 | IL6ST/MARCO ratio | GCST90315167 | 5.83e-04 |
| 9997 | Triglycerides in medium VLDL (UKB data field 23508) | GCST90269605 | 5.82e-04 |
| 9998 | COVID-19 vaccination | GCST90255613 | 5.81e-04 |
| 9999 | Incidence of bisecting GlcNAc in all fucosylated disialylated structures (GP57) | GCST90668735 | 5.79e-04 |
| 10000 | Concentration of small VLDL particles (UKB data field 23509) | GCST90269606 | 5.78e-04 |